-
2024-515384-62-00
5
2020-10-09
Soft Tissue Sarcoma
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2023-505737-26-00
5
2020-07-22
Steroid refractory Acute Graft versus host Disease
-
2022-501050-11-01
10
2020-07-13
Acute Lymphoblastic Leukaemia
-
2024-511904-18-00
10
2020-07-08
Pancreatic adenocarcinoma (PAC)
-
2024-515276-12-00
5
2020-07-01
Postpartum Hemorrhage
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2023-507256-76-00
6
2020-01-14
Ulcerative colitis
-
2024-516266-11-00
5
2020-01-06
yeast intra-abdominal infection, peritonitis
-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2023-507689-26-00
5
2019-10-07
Histologically or cytologically confirmed Locoregional Hepatocellular
-
2024-510580-28-00
5
2019-06-05
Middle or low locally advanced resectable rectal carcinoma
-
2023-508302-24-00
4
2019-05-07
Locally Advanced/Metastatic Urothelial Cancer
-
2024-512629-97-00
4
2019-01-23
Patients with locally advanced or metastatic low grade endometrial str
-
2024-516110-38-00
5
2018-03-06
Hepatoblastoma and Hepatocellular Carcinoma
-
2024-516810-39-00
4
2018-02-13
Adjuvant therapy after salvage surgery of high risk recurrent head and
-
2024-518578-15-00
5
2018-02-05
Is to demonstrate a non inferior efficacy of azithromycin and so the p
-
2024-512827-36-00
4
2016-10-17
Penis carcinoma
-
2024-515432-71-00
5
2016-09-13
gastrointestinal stromal tumor
-
2024-516725-31-00
9
2016-04-14
advanced and metastatic
-
2024-516078-31-00
10
2015-05-05
Recurrent and Primary Refractory Ewing Sarcoma
-
2024-517275-21-00
4
2012-02-20
Retinoblastoma
-
2023-508827-10-00
4
2025-10-13
Patients with primary operable stage II, grade 2 or 3, Ki67 #20%, HR+/
-
2024-515494-95-00
4
2025-05-26
Moderate to Severe Atopic Dermatitis (AD)